Clinical Trials Logo

Purpura, Thrombocytopenic clinical trials

View clinical trials related to Purpura, Thrombocytopenic.

Filter by:

NCT ID: NCT01652599 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT

Start date: June 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the response rate and response duration with the combination of eltrombopag and high-dose dexamethasone

NCT ID: NCT01621204 Completed - Clinical trials for Immune Thrombocytopenic Purpura

A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Start date: October 2012
Phase: Phase 3
Study type: Interventional

This is a study to investigate if eltrombopag can be used instead of Intravenous Immune Globulin (IVIG) in patients with ITP, to adequately raise their platelet count when they undergo minor or major surgery. Eltrombopag is a daily, oral pill approved for treatment of ITP. IVIG is a blood product frequently used to treat ITP. Patients with ITP who need surgery have to get treatment to increase their platelet count. IVIG is commonly used for this purpose but eltrombopag may be more effective and convenient for patients.

NCT ID: NCT01610180 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

Start date: June 2012
Phase: Phase 2
Study type: Interventional

With conventional treatments (i.e. iv Ig, steroids) the overall response rate of ITP secondary to LPD is generally lower than in primary ITP, and usually not higher than 50% (95% CI 27-72). Eltrombopag which has proved very effective in primary ITP could be effective also in ITP secondary to LPDs. This novel ITP specific treatment might spare these patients not only from bleeding risk but also from toxic or inappropriate cytotoxic therapies, not otherwise demanded by the burden of the underlying disease.

NCT ID: NCT01571349 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Hemostasis in Patients With Idiopathic Thrombocytopenic Purpura

Start date: April 2012
Phase: N/A
Study type: Observational

The investigators are trying to investigate the coagulation status of idiopathic (immune) thrombocytopenic purpura patients by measuring the platelet count, coagulation battery, von Willebrand factor level, thromboelastography.

NCT ID: NCT01554514 Completed - Clinical trials for Thrombotic Thrombocytopenic Purpura

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

Start date: August 2012
Phase: Phase 2
Study type: Interventional

Thrombotic thrombocytopenic purpura (TTP) is a disease characterized by small blood clots throughout the body that can damage major organs and cause death. TTP is treated with plasma exchange (also called "plasmapheresis"). Patients who do not respond initially to plasma exchange often are helped by later treatment with rituximab. The purpose of this study is to see whether combining low doses of rituximab with plasma exchange will help patients get better sooner and reduce the chance of getting TTP again.

NCT ID: NCT01549054 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501

Start date: January 2012
Phase: Phase 1
Study type: Interventional

This is a study in healthy subjects. There are two parts to the study. In the first part of the study each subject will receive a single 10mg dose of each of the four formulations of E550. Based on the results from Part 1, an optimal formulation will be selected for further evaluation in Part 2.

NCT ID: NCT01525836 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The project was undertaking by Qilu Hospital of Shandong University and other 13 well-known hospitals in China. In order to report the efficacy and safety of Recombinant Human thrombopoietin combining with Rituximab for the treatment of adults with refractory immune thrombocytopenia (ITP), compared to conventional Rituximab therapy.

NCT ID: NCT01520909 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

PETIT2
Start date: March 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study. In part 1, patients will be randomized to receive either eltrombopag or placebo for 13 weeks. All patients who complete part 1 will enter part 2. In part 2, all patients will receive 24 weeks of eltrombopag.

NCT ID: NCT01510873 Completed - Clinical trials for Immune Thrombocytopenic Purpura

Health-related Quality of Life and Fatigue in Adult Patients With Primary Immune Thrombocytopenic Purpura (pITP)

Start date: December 2011
Phase: N/A
Study type: Observational

Symptoms of Primary Immune Thrombocytopenic Purpura (pITP), such as spontaneous bruising, menorrhagia, mucosal bleeding and other symptoms might significantly affect the HRQOL of pITP patients. However, very little evidence exists on HRQOL outcomes in patients diagnosed with pITP. The investigators project will aim at providing scientific community solid evidence based data on the extent to which HRQOL is compromised and in which specific area. The purpose of this study is thus to compare generic Health-related Quality of Life (HRQOL) profiles of adult patients with primary Immune Thrombocytopenic Purpura (pITP) with that of a matched Italian population control Group.

NCT ID: NCT01506414 Completed - Clinical trials for Idiopathic Thrombocytopenic Purpura

Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

Start date: June 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Recombinant Human Thrombopoietin (rh-TPO) in combination with Rituximab are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).